HK1059789A1 - CD4-gamma2 and cd4-lgg2 chimeras. - Google Patents

CD4-gamma2 and cd4-lgg2 chimeras.

Info

Publication number
HK1059789A1
HK1059789A1 HK04101540A HK04101540A HK1059789A1 HK 1059789 A1 HK1059789 A1 HK 1059789A1 HK 04101540 A HK04101540 A HK 04101540A HK 04101540 A HK04101540 A HK 04101540A HK 1059789 A1 HK1059789 A1 HK 1059789A1
Authority
HK
Hong Kong
Prior art keywords
gamma2
lgg2
chimeras
provides
expression vector
Prior art date
Application number
HK04101540A
Other languages
English (en)
Inventor
Paul J Maddon
Gary A Beaudry
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Publication of HK1059789A1 publication Critical patent/HK1059789A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Regulating Braking Force (AREA)
  • Vehicle Body Suspensions (AREA)
  • Automatic Cycles, And Cycles In General (AREA)
  • Steering Control In Accordance With Driving Conditions (AREA)
  • Control Of Driving Devices And Active Controlling Of Vehicle (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK04101540A 1991-02-08 2004-03-02 CD4-gamma2 and cd4-lgg2 chimeras. HK1059789A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65368491A 1991-02-08 1991-02-08

Publications (1)

Publication Number Publication Date
HK1059789A1 true HK1059789A1 (en) 2004-07-16

Family

ID=24621912

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04101540A HK1059789A1 (en) 1991-02-08 2004-03-02 CD4-gamma2 and cd4-lgg2 chimeras.

Country Status (10)

Country Link
US (2) US6451313B1 (fr)
EP (2) EP1340769B1 (fr)
JP (1) JP3670276B2 (fr)
AT (1) ATE288923T1 (fr)
AU (1) AU660662B2 (fr)
CA (1) CA2080226C (fr)
DE (1) DE69233480T2 (fr)
ES (1) ES2237727T3 (fr)
HK (1) HK1059789A1 (fr)
WO (1) WO1992013947A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340769B1 (fr) * 1991-02-08 2005-02-09 Progenics Pharmaceuticals, Inc. Chimères de CD4-gamma2 et de CD4-IgG2
US7070991B2 (en) * 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
EP0664710A4 (fr) * 1992-08-07 1998-09-30 Progenics Pharm Inc IMMUNOCONJUGUES CD4-GAMMA2 ET CD4-IgG2 A FRACTION CONJUGUEE NON PEPTIDYLE, ET LEURS UTILISATIONS.
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
WO1996002575A1 (fr) * 1994-07-13 1996-02-01 Progenics Pharmaceuticals, Inc. Articles manufactures permettant d'eliminer le vih-1 d'un echantillon, et procedes faisant appel a ces articles
US7368114B2 (en) * 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
JP4870569B2 (ja) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン断片を用いた蛋白質結合体およびその製造方法
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
WO2005089805A2 (fr) * 2004-03-15 2005-09-29 Nektar Therapeutics Al, Corporation Compositions a base de polymeres et conjugues d'inhibiteurs d'entree du vih
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP1989326A4 (fr) 2006-01-17 2009-09-30 Health Research Inc Bio-essai de suivi en heteroduplex
US20080051503A1 (en) * 2006-08-28 2008-02-28 The Goodyear Tire & Rubber Company Method of mixing fiber loaded compounds using a Y-mix cycle
MY151184A (en) 2008-07-23 2014-04-30 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP2013514795A (ja) * 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価ｃｄ４７抗体定常領域融合タンパク質
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
KR20210119546A (ko) * 2014-06-04 2021-10-05 악셀레론 파마 인코포레이티드 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
AU2016238254B2 (en) 2015-03-26 2022-05-05 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
AU616639B2 (en) 1986-08-21 1991-11-07 Trustees Of Columbia University In The City Of New York, The Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
WO1989001940A1 (fr) 1987-09-04 1989-03-09 Biogen, Inc. Sequences d'adn, molecules d'adn recombinant et procedes de production de proteines t4 solubles
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
PT89484B (pt) * 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
IL91070A (en) * 1988-07-23 1995-03-30 Us Commerce Cytotoxic agents against certain viral infections
JPH02107393A (ja) * 1988-10-18 1990-04-19 Asahi Chem Ind Co Ltd 排水中の塩素系溶剤の除去方法
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (fr) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
ATE144793T1 (de) * 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
AU1438592A (en) * 1991-02-08 1992-09-07 Progenics Pharmaceuticals, Inc. Cd4-gamma1 and cd4-igg1 chimeras
EP1340769B1 (fr) * 1991-02-08 2005-02-09 Progenics Pharmaceuticals, Inc. Chimères de CD4-gamma2 et de CD4-IgG2
EP0571536A4 (fr) * 1991-02-12 1995-03-22 Univ Colorado State Res Found Reactifs et procedes d'identification de vaccins.
EP0664710A4 (fr) * 1992-08-07 1998-09-30 Progenics Pharm Inc IMMUNOCONJUGUES CD4-GAMMA2 ET CD4-IgG2 A FRACTION CONJUGUEE NON PEPTIDYLE, ET LEURS UTILISATIONS.

Also Published As

Publication number Publication date
EP1340769B1 (fr) 2005-02-09
JPH05507854A (ja) 1993-11-11
AU660662B2 (en) 1995-07-06
DE69233480T2 (de) 2006-01-05
WO1992013947A1 (fr) 1992-08-20
EP0528011A1 (fr) 1993-02-24
CA2080226A1 (fr) 1992-08-09
AU1440092A (en) 1992-09-07
JP3670276B2 (ja) 2005-07-13
ES2237727T3 (es) 2005-08-01
CA2080226C (fr) 2004-05-04
ATE288923T1 (de) 2005-02-15
EP1340769A1 (fr) 2003-09-03
US6187748B1 (en) 2001-02-13
EP0528011A4 (en) 1993-06-30
US6451313B1 (en) 2002-09-17
DE69233480D1 (de) 2005-03-17

Similar Documents

Publication Publication Date Title
EP0528011A4 (en) Cd4-gamma2 and cd4-igg2 chimeras
PL324574A1 (en) Antiparasitic markfortines and paraherquamides
PL312962A1 (en) Thermally stable xylanases
EP0616488A3 (fr) Eléments émetteurs de lumière.
PL332541A1 (en) D-olanzapin dihydrate
EP0632550A3 (fr) Modulation de diodes laser.
GR3024454T3 (en) Axially-engaged, abrasion-resistant split sprocket assembly.
EP0680198A3 (fr) Imprimante avec boucle de retour optique.
EP0618651A3 (fr) Laser à émission de surface avec modulateur de la lumière.
EP0610648A3 (fr) Appareil de télécommunication à niveaux multiples de codage.
EP0633388A3 (fr) Stabilisateur pour le forage.
EP0631169A3 (fr) Appareil de modulation optique.
DE68905241D1 (en) Tracheobronchodilatator.
EP0590595A3 (fr) Composition de caoutchouc à base de polysiloxane résistant à l'huile.
YU32590A (en) Agents for improving chain for p-phenylenmethylendi-izo-cianatic prepolymers for cast polyurethanic elastomers
EP0650112A3 (fr) Source de courant constante.
EP0627772A3 (fr) Dispositif émetteur de lumière de AlGaInP.
GR3006694T3 (fr)
EP0606092A3 (fr) Elément laser à diode.
EP0685559A4 (fr) Gene de la phospholipase d derive des plantes.
GR3033821T3 (en) Device for coupling at least one light emitting element with at least one light receiving element.
EP0556607A3 (en) Distributed feedback laser diodes with selectively placed lossy sections
EP0632299A3 (fr) Elément optoélectrique avec réseau de réaction.
EP0632429A3 (fr) Quantificateur vectoriel.
EP0611105A3 (fr) Source de courant.

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE FILING DATE OF THE PRIORITY APPLICATION FROM 08.05.1991 TO 08.02.1991

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090210